US 7,320,795 B2 | ||
Rodent hepatitis B virus core proteins as vaccine platforms and methods of use thereof | ||
David R. Milich, Escondido, Calif. (US); and Jean-Noel Billaud, San Diego, Calif. (US) | ||
Assigned to Vaccine Research Institute of San Diego, San Diego, Calif. (US) | ||
Filed on Jul. 30, 2003, as Appl. No. 10/630,070. | ||
Prior Publication US 2005/0025781 A1, Feb. 03, 2005 | ||
Int. Cl. A61K 39/29 (2006.01); A61K 39/295 (2006.01); C12N 15/51 (2006.01); C12N 15/62 (2006.01) |
U.S. Cl. 424—189.1 [424/192.1; 424/227.1; 536/23.72; 536/23.4; 435/320.1] | 28 Claims |
1. An antigenic composition comprising a heterologous antigen inserted within the amino acid sequence set forth in SEQ ID NO:38, wherein said heterologous antigen is 50 or fewer amino acids in length and is inserted at a position chosen from amino acid residues 44, 71, 72, 73, 74, 75, 76, 77, 78, 81, 82, 83, 84, 85, or 92 of SEQ ID NO:38, and wherein said heterologous antigen and said amino acid sequence assemble as a hybrid particle. |